製品名:8-Chloro-2-(methylthio)pyrimido[5,4-d]pyrimidine

IUPAC Name:8-chloro-2-(methylsulfanyl)pyrimido[5,4-d][1,3]diazine

CAS番号:176637-10-8
分子式:C7H5ClN4S
純度:95%+
カタログ番号:CM167362
分子量:212.66

包装単位 有効在庫 価格(USD) 数量
CM167362-250mg in stock ǶưƦ
CM167362-500mg in stock ȺƎȺ
CM167362-1g in stock ƎNJƎ
CM167362-5g 1-2 Weeks ǶȡƦƦ
CM167362-10g 1-2 Weeks ũȺƦȡ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:176637-10-8
分子式:C7H5ClN4S
融点:-
SMILESコード:CSC1=NC=C(N=CN=C2Cl)C2=N1
密度:
カタログ番号:CM167362
分子量:212.66
沸点:
MDL番号:MFCD00227587
保管方法:Store at 2-8°C.

Column Infos

Zongertinib
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients.
Zongertinib (also known as BI 1810631) is an investigational oral HER2-specific tyrosine kinase inhibitor (TKI) that is being developed as a potential treatment for HER2 mutated non-small cell lung cancer (NSCLC). Zongertinib was granted FDA Fast Track Designation in 2023, then in 2024 it was granted Breakthrough Therapy Designation by the U.S. FDA and China CDE for the treatment of adult patients with advanced NSCLC whose tumors have activating HER2 mutations, and who have received a prior systemic therapy.

Related Products